Expert Review of Clinical Immunology最新文献_第9页

Toward a personalized therapy of still's disease based on immunologic endotypes: a narrative review. 基于免疫内型的斯蒂尔氏病个体化治疗：叙述性回顾。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-02-11 DOI: 10.1080/1744666X.2025.2465406

Po-Ku Chen, Shiow-Jiuan Wey, Der-Yuan Chen

{"title":"Toward a personalized therapy of still's disease based on immunologic endotypes: a narrative review.","authors":"Po-Ku Chen, Shiow-Jiuan Wey, Der-Yuan Chen","doi":"10.1080/1744666X.2025.2465406","DOIUrl":"10.1080/1744666X.2025.2465406","url":null,"abstract":"Introduction: Accumulative evidence indicates that both innate and adaptive immunity are involved in pathogenesis of Still's disease, an autoinflammatory disease. With Increasing insights into the pathogenesis of Still's disease coupled with the availability of emerging targeted therapeutics, it may be the unmet need for personalizing therapy and achieving a treat-to-target goal. We aim to summarize the available evidence regarding immunopathogenesis of Still's disease and therapeutic strategies based on immunologic endotypes.Areas covered: We searched MEDLINE database using the PubMed interface and reviewed relevant English-language literature from 1971 to 2024. This review focuses on the existing evidence on pathophysiology and immunological endotypes of Still's disease and their implications for personalized strategies for patients with this disease.Expert opinion: Targeting the complex immunopathogenesis of Still's disease, emerging new agents are available for treatment, including biologic disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) such as Janus kinase inhibitors (JAKi). According to the updated evidence, meta-analyses, and recommendations, we propose a flow chart emphasizing personalized therapeutic strategies based on immunological endotypes. Hopefully, the therapeutic strategy might help guide the optimal selection of b/tsDMARDs to achieve a 'treat-to-target' goal in Still's disease. This proposed flow chart will be updated as newer evidence emerges.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"401-412"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical treatments in special populations of atopic dermatitis - Chinese perspective. 特应性皮炎特殊人群的局部治疗——中国视角。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-03-05 DOI: 10.1080/1744666X.2025.2473726

Hongyu Ruan, Xiaoxia Zhu, Suling Xu, Qiongyan Zhou, Feng Yang, Guixiu Li

{"title":"Topical treatments in special populations of atopic dermatitis - Chinese perspective.","authors":"Hongyu Ruan, Xiaoxia Zhu, Suling Xu, Qiongyan Zhou, Feng Yang, Guixiu Li","doi":"10.1080/1744666X.2025.2473726","DOIUrl":"10.1080/1744666X.2025.2473726","url":null,"abstract":"Introduction: Atopic Dermatitis (AD) is a common chronic, recurrent inflammatory skin disease, characterized mainly by polymorphic skin lesions and severe itching, significantly affecting patients' physical and mental health. The pathogenesis of AD is complex, involving multiple factors such as genetics, environment, immunity, and microbiota. In terms of treatment, traditional systemic therapies are gradually being replaced by more targeted molecular immunotherapies, and the range of topical medications has become more diverse. However, research on AD treatment in special populations, such as children, pregnant women, lactating women, and the elderly, remains relatively limited.Areas covered: This review aims to discuss the research progress on topical treatments for AD in special populations both domestically and internationally, with a focus on personalized treatment approaches. It covers many aspects such as hormones, antimicrobial drugs, small molecule drugs, nanotechnology and microecological therapies, and proposes personalized treatments for each group and problems that need to be solved by current research.Expert opinion: Special populations have unique physiological characteristics, which may lead to different responses to topical medications. Therefore, personalized treatment strategies are especially important in this context. As insights into pathogenesis evolves, the novel therapies are on the rise, holding promise for more targeted treatment approaches.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"425-434"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

French Guiana and AGS: a path to uncovering hidden clues. 法属圭亚那和AGS：一条发现隐藏线索的道路。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-03-10 DOI: 10.1080/1744666X.2025.2475984

Evrard Baduel, Magdalena Smilov, Loïc Epelboin

{"title":"French Guiana and AGS: a path to uncovering hidden clues.","authors":"Evrard Baduel, Magdalena Smilov, Loïc Epelboin","doi":"10.1080/1744666X.2025.2475984","DOIUrl":"10.1080/1744666X.2025.2475984","url":null,"abstract":"Introduction: This article is a narrative review exploring how research in French Guiana could unlock the mysteries surrounding Alpha-Gal Syndrome (AGS), a recently identified IgE-mediated allergy with delayed reactions to exposure to non-Catarrhine mammalian-derived products. Although fewer than 10 cases have been reported across Latin America, two case series involving 11 and 18 patients with AGS have been documented in French Guiana.Areas covered: This article discusses risk factors such as ethnicity, prior pathogen-induced immunization to α-Gal, vectors responsible for AGS, their environment and ecosystems, observed phenotypes, and therapeutic implications for sensitized individuals. Literature research was based on PubMed between 12/2023 and 08/2024, using: α-Gal/Alpha-1,3-Galactose/galactose-α 1,3-galactose/Red meat allergy/Mammalian meat allergy/Alpha gal syndrome/Antivipmyn. Grey literature from French Guiana were obtained from Prof. Loïc Epelboin.Expert opinion: Advancing AGS research in French Guiana could yield valuable epidemiological insights, as existing data predominantly stem from European, North American, Australian, and Japanese contexts - regions with comparatively lower diversity in tick species, their mammalian hosts, associated pathogens, and parasitic infestations. Additionally, French Guiana presents unique therapeutic scenarios, such as Viperidae envenomation and transfusions under inventory constraints, that merit further investigation.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"507-519"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives. 生物制剂和小分子：儿童和青少年特应性皮炎治疗的再进化。当前的艺术状态和未来的展望。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-01-20 DOI: 10.1080/1744666X.2025.2452247

Enza D'Auria, Cristiana Indolfi, Miriam Acunzo, Giulio Dinardo, Pasquale Comberiati, Diego Peroni, Gian Vincenzo Zuccotti, Michele Miraglia Del Giudice

{"title":"Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives.","authors":"Enza D'Auria, Cristiana Indolfi, Miriam Acunzo, Giulio Dinardo, Pasquale Comberiati, Diego Peroni, Gian Vincenzo Zuccotti, Michele Miraglia Del Giudice","doi":"10.1080/1744666X.2025.2452247","DOIUrl":"10.1080/1744666X.2025.2452247","url":null,"abstract":"Introduction: In recent years, the understanding of atopic dermatitis (AD) pathogenetic mechanisms has expanded, and now it is recognized that Th2 immune axis dysregulation is pivotal to AD pathogenesis. The advent of biological drugs and small molecules has marked a revolution in the treatment of AD. Dupilumab, targeting IL-4 and IL-13, has been the first to demonstrate efficacy in treating moderate to severe AD by modulating type-2 inflammation pathways. Increasing knowledge of different immune axis and cytokines has fueled the development of new biologics and small molecules. JAK inhibitors, which target the JAK-STAT pathway, involved in cytokine signaling, represent a promising novel therapeutic strategy, enlarging the treatment options for moderate to severe atopic dermatitis.Areas covered: This comprehensive review aims to provide an updated and critical overview of the drugs currently in use and under investigation for the treatment of moderate to severe AD in children and adolescents, along with addressing the unmet needs and future research perspectives.Expert opinion: Biologics and small molecules offer the promise to enlarge the arsenal options for the treatment of AD. Since the patients' response to biologics depends on AD pheno-endotype, choosing the right biologic is crucial for ensuring therapy success.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"493-505"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological therapy in chronic rhinosinusitis with nasal polyps. 慢性鼻炎伴鼻息肉的生物疗法。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-01-31 DOI: 10.1080/1744666X.2025.2459929

Zeyi Jin, Bing Yan, Luo Zhang, Chengshuo Wang

{"title":"Biological therapy in chronic rhinosinusitis with nasal polyps.","authors":"Zeyi Jin, Bing Yan, Luo Zhang, Chengshuo Wang","doi":"10.1080/1744666X.2025.2459929","DOIUrl":"10.1080/1744666X.2025.2459929","url":null,"abstract":"Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease. High proportions of patients with CRSwNP characterized by type 2 inflammation fail to gain adequate control with conventional treatment. The application of biologics in clinics and assessments of novel biologics in clinical trials are blooming in expectations to fulfill the unmet medical needs of patients with CRSwNP with type 2 inflammation.Areas covered: After an extensive search of PubMed, Medline, and EMBASE for the most recent evidence, we thoroughly summarize current advances in biological therapies for treating patients with CRSwNP.Expert opinion: In recent years, biological therapy has been in the spotlight in clinical studies on CRSwNP. Biologics have proven to be efficacious in reducing nasal polyp size, alleviating CRSwNP-related symptoms, improving quality of life, and reducing the need for systemic corticosteroids or endoscopic sinus surgery for nasal polyps. The considerable efficacy and safety profile of biologics has offered patients with refractory CRSwNP another treatment option. However, some concerns remain to be addressed. Aspects such as the position of biological therapy in the management of CRSwNP, traits of patients suitable for certain biologics, etc. necessitate efforts to elucidate these unknowns in order to provide patients with tailored therapy.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"473-492"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT). 2型炎症：使用Web-Delphi和决策会议（INFLAT2-PT）的葡萄牙共识。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-07 DOI: 10.1080/1744666X.2024.2448990

Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa

{"title":"Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT).","authors":"Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa","doi":"10.1080/1744666X.2024.2448990","DOIUrl":"10.1080/1744666X.2024.2448990","url":null,"abstract":"Objectives: Atopic/allergic diseases impose a growing burden on public health, affecting millions of patients worldwide. The main objective of this study was to develop a national expert consensus on relevant clinical questions related to type 2 inflammation.Methods: We conducted: a comprehensive literature review with a qualitative analysis to identify the most repeated themes on the overlap of conditions; a modified 3-round Web-Delphi (or e-Delphi); and a final online decision conference.Results: We included 51 studies. Following three Web-Delphi rounds, we ended up with 30 statements with a 76% overall full agreement rate, 16% agreement, 2% disagreement, and 0% full disagreement. The decision conference enabled adjustments, and the expert panel agreed unanimously on the final set of statements. The consensus used evidence synthesis, Web-Delphi, and decision conference to produce 30 statements on type 2 inflammation as a driver for multimorbidity in asthma, certain rhinitis phenotypes, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis grouped under five domains in underlying pathophysiology, multimorbidity, diagnosis and management, multidisciplinary management, and impact on mental health.Conclusion: We expect the first Portuguese expert consensus INFLAT2-PT to promote understanding of type 2 inflammation diseases, multidisciplinary care, integrated care pathways, future research, and inform health authorities.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"377-391"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in tumor immunotherapy targeting macrophages. 靶向巨噬细胞的肿瘤免疫治疗研究进展。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI: 10.1080/1744666X.2024.2438721

Binrui Shi, Meng Du, Zhiyi Chen

{"title":"Advances in tumor immunotherapy targeting macrophages.","authors":"Binrui Shi, Meng Du, Zhiyi Chen","doi":"10.1080/1744666X.2024.2438721","DOIUrl":"10.1080/1744666X.2024.2438721","url":null,"abstract":"Introduction: In recent years, immunotherapy has shown significant therapeutic potential in patients with advanced tumors. However, only a small number of individuals benefit, mainly due to the tumor microenvironment (TME), which provides conditions for the development of tumors. Macrophages in TME, known as tumor-associated macrophages (TAM), are mainly divided into M1 anti-tumor and M2 pro-tumor phenotypes, which play a regulatory role in various stages of tumorigenesis, promote tumorigenesis and metastasis, and cause immunotherapy resistance.Areas covered: This review focuses on research strategies and preclinical/clinical research progress in translating TAM into antitumor phenotype by referring to the PubMed database for five years. These include small molecule chemotherapy drug development, metabolic regulation, gene editing, physical stimulation, nanotechnology-mediated combination therapy strategies, and chimeric antigen receptor-based immunotherapy.Expert opinion: It is necessary to explore the surface-specific receptors and cell signaling pathways of TAM further to improve the specificity and targeting of drugs and to strengthen research in the field of probes that can monitor changes in TAM in real time. In addition, the physical stimulation polarization strategy has the advantages of being noninvasive, economical, and stable and will have excellent clinical transformation value in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"259-276"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The "entanglement" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations. 大疱性类天疱疮与糖尿病之间的 "纠葛"：全面回顾与专家建议。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-11-13 DOI: 10.1080/1744666X.2024.2428621

Jing-Hui Li, Ya-Gang Zuo

{"title":"The \"entanglement\" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations.","authors":"Jing-Hui Li, Ya-Gang Zuo","doi":"10.1080/1744666X.2024.2428621","DOIUrl":"10.1080/1744666X.2024.2428621","url":null,"abstract":"Introduction: Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by subepidermal tense blisters, accompanied by urticarial or eczema-like lesions. Circulating autoantibodies in BP patients target BP180 and BP230 at the dermal-epidermal junction. There has been a growing interest in unraveling the intricate relationship between BP and diabetes mellitus (DM), but a comprehensive review is lacking.Areas covered: A thorough search of PubMed was conducted to identify studies concerning the association between BP and DM (1978-2023). Our findings comprehensively summarize the intricate association between BP and DM, focusing on the characteristics, potential pathomechanisms, and the influence of various antidiabetic medications on BP development.Expert opinion: DM emerges as a prevalent comorbidity and potential risk factor for BP. New-onset DM can manifest during BP treatment, primarily due to corticosteroid therapy. Among all antidiabetic medications, dipeptidyl peptidase-IV inhibitors (DPP-4i) have the most solid association with BP onset. Other antidiabetic medications have also been reportedly associated with BP, including meglitinides, glucagon-like peptide 1 (GLP-1)-receptor agonists, and sodium-dependent glucose transporters 2 inhibitors (SGLT-2i). We suggest prescribing DPP-4i in caution for elderly DM patients with a history of autoimmune diseases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"333-346"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies. 嵌合抗原受体后的噬血细胞淋巴组织细胞病T细胞治疗。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-30 DOI: 10.1080/1744666X.2024.2444673

Jing-Ming Wang, Hui-Wen Jiang, Yin-Qiang Zhang, Yu Hu, Heng Mei

{"title":"Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies.","authors":"Jing-Ming Wang, Hui-Wen Jiang, Yin-Qiang Zhang, Yu Hu, Heng Mei","doi":"10.1080/1744666X.2024.2444673","DOIUrl":"10.1080/1744666X.2024.2444673","url":null,"abstract":"Introduction: Besides cytokine release syndromes (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated HLH-like syndrome (IEC-HS) is increasingly recognized across CAR-T recipients. This emergent and fatal syndrome is difficult to separate from other disorders during the early phase, and urgently requires more integrated diagnostic and therapeutic frameworks.Areas covered: Existing literature has pointed out the potential role of unbridled proliferation of cytotoxic T lymphocytes, lymphopenia of natural killing cells, and hypercytokinemia in triggering the IEC-HS. The onset time of IEC-HS usually overlaps with CRS or be delayed from CRS. Clinical features include hyperferritinemia, hepatic and renal dysfunctions, cytopenias, coagulopathy, and hemophagocytosis. Multiple diagnostic criteria are based predominantly on ferritin elevation and prerequisite CRS. Corticosteroids are the cornerstone for IEC-HS treatment, while cytokine-targeted agents and pathway inhibitors offer great promise in alleviating IEC-HS syndromes.Expert opinions: Several controversial predisposing factors of IEC-HS such as disease burden should be further investigated. Future research is anticipated to identify the real-time biomarkers, as well as develop a more sophisticated grading and management network.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"277-289"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplantation. 异体造血干细胞移植的感染并发症及血清和细胞感染标志物的应用。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-08 DOI: 10.1080/1744666X.2025.2450014

Håkon Reikvam, Galina Tsykunova, Miriam Sandnes, Øystein Wendelbo

{"title":"Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplantation.","authors":"Håkon Reikvam, Galina Tsykunova, Miriam Sandnes, Øystein Wendelbo","doi":"10.1080/1744666X.2025.2450014","DOIUrl":"10.1080/1744666X.2025.2450014","url":null,"abstract":"Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are severely immunocompromised and susceptible to bacterial, viral, and fungal infections. Despite improved anti-microbial prophylaxis and preemptive strategies, bacterial bloodstream infections (BSIs) occur frequently in allo-HSCT recipients and are associated with increased morbidity and mortality. Cytomegalovirus (CMV) and Epstein Barr virus (EBV) are the most relevant viruses following allo-HSCT and remain major concerns. Fungal infections, including those caused by Candida and Aspergillus species, are persistent and feared complications.Areas covered: We aim to provide clinicians caring for allo-HSCT recipients with a comprehensive overview of the risk factors that predispose patients to common bacterial, fungal, and viral infections during the first years post-transplant. The focus is on the value of noninvasive diagnostic biomarkers and serological assays in enhancing the early detection and management of these infections.Expert opinion: Effective management of infectious complications following allo-HSCT relies on continuous immune recovery monitoring and the implementation of advanced diagnostic methods. Utilizing noninvasive diagnostic methods is crucial for early detection and different intervention strategies. The development and integration of reliable microbiological markers into clinical practice is essential for enhancing patient outcomes and mitigating infection-related risks. Emphasizing diagnostic innovation will be pivotal in advancing patient care post-allo-HSCT.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"291-303"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0